Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy (original) (raw)

• Tallman MS, Gillliland DG, Rowe JM . Drug therapy for acute myeloid leukemia. Blood 2005; 106: 1154–1163.
  Article CAS PubMed Google Scholar
• Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994; 370: 527–532.
  CAS PubMed Google Scholar
• Vey N, Mozzinconacci MJ, Groulet-Martinec A, Debono S, Finetti P, Carbuccia N et al. Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling. Oncogene 2004; 23: 9381–9391.
  CAS PubMed Google Scholar
• Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998; 12: 1333–1337.
  CAS PubMed Google Scholar
• Shimada A, Taki T, Tabuchi K, Tawa A, Horibe K, Tsuchida M et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood 2006; 107: 1806–1809.
  CAS PubMed Google Scholar
• Christiansen DH, Andersen MK, Desta F, Pedersen-Bjergaard J . Mutations of genes in the receptor tyrosine kinase (RTK) RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2005; 19: 2232–2240.
  CAS PubMed Google Scholar
• Padua RA, Guinn BA, Al-Sabah AI, Smith M, Taylor C, Pettersson T et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia 1998; 12: 887–892.
  CAS PubMed Google Scholar
• Dong F, Brynes RK, Tidow N, Welte K, Lowenberg B, Touw IP . Mutations in the gene for granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceeded by severe congenital neutropenia. N Engl J Med 1995; 333: 487–493.
  CAS PubMed Google Scholar
• Dong F, Dale DC, Bonilla MA, Freedman M, Fasth A, Neijens HJ et al. Mutations in the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia. Leukemia 1997; 11: 120–125.
  CAS PubMed Google Scholar
• Hiramatsu A, Miwa H, Shikami M, Ikai T, Tajima E, Yamamoto H et al. Disease-specific expression of VEGF and its receptors in AML cells; possible autocrine pathway of VEGF/type-1 receptor of VEGF in t(15;17) and AML in VEGF/type2 receptor of VEGF in t(8;21) AML. Leuk Lymph 2006; 47: 89–95.
  CAS Google Scholar
• Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S . Implications of NRAS mutations in AML: a study of 2502 patients. Blood. 2006; 107: 3847–3853.
  CAS PubMed Google Scholar
• Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, Milella M et al. Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia 2004; 18: 267–275.
  CAS PubMed Google Scholar
• Gregorj C, Ricciardi MR, Petrucci MT, Scerpa MC, DeCave F, Fazi P et al. ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 2007; 109: 5473–5476.
  CAS PubMed Google Scholar
• Milella M, Konopleva M, Precupanu CM, Tabe Y, Ricciardi MR, Gregorj C et al. MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood 2007; 109: 2121–2129.
  CAS PubMed Google Scholar
• Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001; 108: 851–859.
  CAS PubMed PubMed Central Google Scholar
• Staber PB, Linkesch W, Zauner D, Beham-Schmid C, Guelly C, Schauer S et al. Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia. Oncogene 2004; 29: 894–904.
  Google Scholar
• Stone RM, O’Donnell MR, Sekeres MA . Acute myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2004; 1: 98–117.
  Google Scholar
• Birkenkamp KU, Geugien M, Schepers H, Westra J, Lemmink HH, Vellenga E . Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia 2004; 18: 103–112.
  CAS PubMed Google Scholar
• Stirewalt DL, Radich JP . The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003; 3: 650–665.
  CAS PubMed Google Scholar
• Meshinchi S, Stirewalt DL, Alonzo TA, Zhang Q, Sweetser DA, Woods WG et al. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood 2003; 102: 1474–1479.
  CAS PubMed Google Scholar
• Yokota S, Nakao M, Horiike S, Seriu T, Iwai T, Kaneko H et al. Mutational analysis of the N-ras gene in acute lymphoblastic leukemia: a study of 125 Japanese pediatric cases. Int J Hematol 1998; 67: 379–387.
  CAS PubMed Google Scholar
• Hoelzer D, Gokbuget N . Recent approaches in acute lymphoblastic leukemia in adults. Crit Rev Oncol Hematol 2000; 36: 49–58.
  CAS PubMed Google Scholar
• Pui CH, Evans WE . Genetic abnormalities and drug resistance in acute lymphoblastic leukemia. Adv Exp Med Biol 1999; 457: 383–389.
  CAS PubMed Google Scholar
• Tazzari PL, Cappellini A, Ricci F, Papa V, Evangelisti C, Grafone T et al. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 2007; 21: 427–438.
  CAS PubMed Google Scholar
• Falini B, Nicletti I, Martelli MF, Mecucci C . Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc + AML): biological and clinical features. Blood. 2007; 109: 874–885.
  CAS PubMed Google Scholar
• Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531–2541.
  CAS PubMed Google Scholar
• Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005; 105: 54–60.
  Article CAS PubMed Google Scholar
• Lancet JE, Gogo I, Gotib J, Feldman EJ, Greer J, Liesveld JL et al. A phase 2 study of the farnesyltransferase inhibitor tipifarinib in poor risk and elderly patients with previously untreated acute myeloid leukemia. Blood 2007; 109: 1387–1394.
  CAS PubMed PubMed Central Google Scholar
• Faderl S, Kantarjian HM, Estey E, Manshouri T, Chan CY, Rahman Elsaied A et al. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer 2000; 89: 1976–1982.
  CAS PubMed Google Scholar
• Harris SL, Levine AJ . The p53 pathway: positive and negative feedback loops. Oncogene 2005; 24: 2899–2908.
  CAS PubMed Google Scholar
• Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005; 106: 3150–3159.
  CAS PubMed PubMed Central Google Scholar
• Konopleva M, Contractor R, Tsao T, Samudio L, Ruvolo PP, Kitada S et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375–388.
  Article CAS PubMed Google Scholar
• Kojima K, Konopleva M, McQueen T, O’Brien S, Plunkett W, Andreeff M . MDM2 inhibitor Nutlin 3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006; 108: 993–1000.
  CAS PubMed PubMed Central Google Scholar
• Steelman LS, Bertrand FE, McCubrey JA . The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opin Ther Targets 2004; 8: 537–550.
  CAS PubMed Google Scholar
• Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PN, Blalock WL et al. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway. Int J Oncol 2003; 22: 469–480.
  CAS PubMed Google Scholar
• Martelli AM, Tazzari PL, Evangelisti C, Chiarini F, Blalock WL, Billi AM et al. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr Med Chem 2007; 14: 2009–2023.
  CAS PubMed Google Scholar
• Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ . p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule Bad. Proc Natl Acad Sci USA 2001; 98: 9666–9670.
  CAS PubMed PubMed Central Google Scholar
• Navolanic PM, Steelman LS, McCubrey JA . EGFR family signaling and its association with breast cancer development and resistance to chemotherapy. Int J Oncol 2003; 22: 237–252.
  CAS PubMed Google Scholar
• Deng X, Xiao L, Lang W, Gao F, Ruvolo P, May Jr WS . Novel role for JNK as a stress-activated Bcl2 kinase. J Biol Chem 2001; 276: 23681–23688.
  CAS PubMed Google Scholar
• Hollestelle A, Elstrodt F, Nagel JHA, Kallemeijn WW . Phosphatidylinositol-3-OH kinase or Ras pathway mutations in human breast cancer cell lines. Mol Cancer Res 2007; 5: 195–201.
  Article CAS PubMed Google Scholar
• Lee Jr JT, McCubrey JA . The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention. Leukemia 2002; 16: 486–507.
  CAS PubMed Google Scholar
• Barnes G, Bulusu VR, Hardwick RH, Carroll N, Hatcher H, Earl HM et al. A review of the surgical management of metastatic gastrointestinal stromal tumours (GISTs) on imatinib mesylate (Glivectrade mark). Int J Surg 2005; 3: 206–212.
  CAS PubMed Google Scholar
• Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR et al. Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumors and hematological malignancies. Curr Drug Design 2007; 10: 81–100.
  CAS Google Scholar
• Zeng Z, Sarbassov D, Samudio IJ, Yee KW, Munsell F, EllenJackson L et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007; 109: 3509–3512.
  CAS PubMed PubMed Central Google Scholar
• Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65: 7052–7058.
  CAS PubMed Google Scholar
• Tamburini J, Chapuis N, Burdet V, Park S, Sujobert P, Willems L et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008; 111: 379–382.
  CAS PubMed Google Scholar
• Shelton JG, Moye PW, Steelman LS, Blalock WL, Lee JT, Franklin RA et al. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia 2003; 17: 1765–1782.
  CAS PubMed Google Scholar
• Heimbrook DC, Huber HE, Stirdivant SM, Claremon D, Liverton N, Patrick DR et al. Identification of potent, selective kinase inhibitors of Raf. Proc Am Assoc Cancer Res Annual Meeting 1998; 39: 558.
  Google Scholar
• Hall-Jackson CA, Eyers PA, Cohen P, Goedert M, Boyle FT, Hewitt N et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol 1999; 6: 559–568.
  CAS PubMed Google Scholar
• Lyons JF, Wilhelm S, Hibner B, Bollag G . Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001; 8: 219–225.
  CAS PubMed Google Scholar
• Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RI, Bommann WJ et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008; e-pub ahead of print Jan 17 (in press).
• Blagosklonny MV . Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia 2002; 16: 455–462.
  CAS PubMed Google Scholar
• Workman P . Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 2004; 10: 47–51.
  CAS PubMed Google Scholar
• Nimmanapalli R, Bhalla K . Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571. Oncogene 2002; 21: 8584–8590.
  CAS PubMed Google Scholar
• Hawkins LM, Jayanthan AA, Narendran A . Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity. Pediatr Res 2005; 57: 430–437.
  CAS PubMed Google Scholar
• Milella M, Precupanu CM, Gregorj C, Ricciardi MR, Petrucci MT, Kornblau SM . Tafuri A, Andreeff M. Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Curr Pharm Des 2005; 11: 2779–2795.
  CAS PubMed Google Scholar
• Mazzucchelli C, Vantaggiato C, Ciamei A, Fasano S, Pakhotin P, Krezel W et al. Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory. Neuron 2002; 34: 807–820.
  CAS PubMed Google Scholar
• Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM et al. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 2008; 22: 147–160.
  CAS PubMed Google Scholar
• Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 2006; 20: 911–928.
  CAS PubMed Google Scholar
• Rolfe M, McLeod LE, Pratt PF, Proud CG . Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2). Biochem J 2005; 388: 973–984.
  CAS PubMed PubMed Central Google Scholar
• Crossman LC, O’Hare T, Lange T, Willis SG, Stoffregen EP, Corgbin AS et al. A signle nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib. Leukemia 2005; 19: 1859–1862.
  CAS PubMed Google Scholar
• Brendel C, Scharenberg C, Dohse M, Robey RW, Bates SE, Shukla S et al. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007; 21: 1267–1275.
  CAS PubMed Google Scholar
• Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926–935.
  CAS PubMed Google Scholar
• Barnes DJ, De S, van Hensbergen P, Moravcsilk E, Melo JV . Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines. Leukemia 2007; 21: 421–426.
  CAS PubMed Google Scholar
• Sherbenou DW, Wong MJ, Humayun A, McGreevey LS, Harrell P, Yang R et al. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia 2007; 21: 489–493.
  CAS PubMed Google Scholar
• Crescenzi B, Chase A, Starza RL, Beacci D, Rosti V, Galli A et al. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells. Leukemia 2007; 21: 397–402.
  CAS PubMed Google Scholar
• Pocaly M, Lagarde V, Etienne G, Ribeil JA, Claverol S, Bonneu M et al. Overexpresion of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia. Leukemia 2007; 21: 93–101.
  CAS PubMed Google Scholar
• Ma W, Kantarjian H, Jilani I, Gorre M, Bhalla K, Ottmann O et al. Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA. Leukemia 2006; 20: 1989–1991.
  CAS PubMed Google Scholar
• Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O’Brien S et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006; 20: 1767–1773.
  CAS PubMed Google Scholar
• Chung Y-J, Kim T-M, Kim D-M, Namkoong H, Kim HK, Ha S-A et al. Gene expression signatures associated with the resistance to imatinib. Leukemia 2006; 20: 1542–1550.
  CAS PubMed Google Scholar
• Frank O, Brors B, Fabarius A, Li L, Haak M, Merk S et al. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia 2006; 20: 1400–1407.
  CAS PubMed Google Scholar
• Nicolini FE, Corm S, Le Q-H, Sorel N, Hayette S, Bories D et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP0. Leukemia 2006; 20: 1061–1066.
  CAS PubMed Google Scholar
• Zheng C, Li L, Haak M, Brors B, Frank O, Giehl M et al. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 2006; 20: 1028–1034.
  CAS PubMed Google Scholar
• Cilloni D, Messa F, Arruga F, Defilippi I, Morotti A, Messa E et al. The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia 2006; 20: 61–67.
  CAS PubMed Google Scholar
• Miething C, Feihl S, Mugler C, Grundler R, von Bubnoff N, Lordick F et al. The Bcr-Abl mutations T3151 and Y253 H do not confer a growth advantage in the absence of imatinib. Leukemia 2006; 20: 650–657.
  CAS PubMed Google Scholar
• Khrashad JS, Anand M, Marin D, Saunders S, Al-Jabary T, Iqbal A et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 2006; 20: 939–940.
  Google Scholar
• Rea D, Legros L, Raffoux E, Thomas X, Turlure P, Maury S et al. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia 2006; 20: 400–403.
  CAS PubMed Google Scholar
• Alvarez-Larran A, Cervantes F, Bellosillo B, Giralt M, Julia A, Hernandez-Boluda JC et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia 2007; 21: 1218–1223.
  CAS PubMed Google Scholar
• Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007; 21: 1183–1188.
  CAS PubMed Google Scholar
• Jost E, Do ON, Dahl E, Maintz CE, Jousten P, Habets L et al. Epigenetic alterations complement mutation of Jak2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia 2007; 21: 505–510.
  CAS PubMed Google Scholar
• Mesa RA, Tefferi A, Lasho TS, Loegering D, McClure RF, Powell HL et al. Janus kinase (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis ion myelofibrosis with myeloid metaplasia. Leukemia 2006; 20: 1800–1808.
  CAS PubMed Google Scholar
• Steensma DP, Caudill JS, Pardanani A, McClure RF, Lasho TL, Tefferi A . MPL W515 and Jak2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count. Leukemia 2006; 20: 971–978.
  CAS PubMed Google Scholar
• Vannucchi AM, Pancrazzi A, Bogani C, Antonioli E, Guglielmelli P . A quantitative assay for Jak2 (V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia 2006; 20: 1055–1060.
  CAS PubMed Google Scholar
• DeKeersmaecker K, Cools J . Chronic myeloproliferative disorders: a tyrosine kinase tale. Leukemia 2006; 20: 200–205.
  CAS Google Scholar
• Bellosillo B, Martinez-Aviles L, Gimeno E, Florensa L, Longaron R, Navarro G et al. A higher Jak2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis. Leukemia 2007; 21: 1331–1332.
  CAS PubMed Google Scholar
• Nishii K, Nanbu R, Lorenzo VF, Monma F, Kato K, Ryuu H et al. Expression of the Jak2 V617F mutation is not found in de novo AML and MDS but is detected in MDS-derived leukemia of megakaryoblastic nature. Leukemia 2007; 21: 1337–1338.
  CAS PubMed Google Scholar
• Pardanani A . JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008; 22: 23–30.
  Article CAS PubMed Google Scholar
• Wong CLP, Ma ESK, Wang CLN, Lam HY, Ma SY . Jak2 V617F due to a novel TG → CT mutation at nucleotides 1848–1849: diagnostic implication. Leukemia 2007; 21: 1344–1346.
  CAS PubMed Google Scholar
• Ohyashiki K, Aota Y, Akahane D, Gotoh A, Ohyashiki JH . Jak2(V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders. Leukemia 2007; 21: 1097–1099.
  CAS PubMed Google Scholar
• Hermouet S, Dobo I, Lippert E, Boursier M-C, Ergand L, Perrault-Hu F et al. Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of Jak2(V617F). Leukemia 2007; 21: 1128–1130.
  CAS PubMed Google Scholar
• Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H et al. Polycythemia associated with the Jak2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia 2007; 21: 1103–1104.
  CAS PubMed Google Scholar
• Schnittger S, Bacher Uk, Kern W, Haferlach C, Haferlach T . Jak2 seems to be a typical cooperating mutation in therapy-related t(8;21)/AML1-ETO-positive AML. Leukemia 2007; 21: 183–184.
  CAS PubMed Google Scholar
• Verstovsek S, Silver RT, Cross NC, Tefferi A . Jak2V617F mutational frequency in polycythemia vera: 100%, >90%. Leukemia 2006; 20: 2067.
  CAS PubMed Google Scholar
• Mesa RA, Tefferi A, Li CY, Steensma DP . Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from Jak2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome. Leukemia 2006; 20: 2063–2064.
  CAS PubMed Google Scholar
• Renneville A, Quesnel B, Charpentier A, Terriou L, Crinquette A, Lai JL . High occurrence of Jak2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia 2006; 20: 2067–2070.
  CAS PubMed Google Scholar
• Ceesay MM, Lea NC, Ingram W, Westwood NB, Gäken J, Mohamedali A et al. The Jak2 V617F mutation is rare in RARS but common in RARS-T. Leukemia 2006; 20: 2060–2061.
  CAS PubMed Google Scholar
• Di Ianni M, Moretti L, Del Papa B, Gaozza E, Bell AS, Falzetti F et al. A microelectronic DNA chip detects the V617F Jak-2 mutation in myeloproliferative disorders. Leukemia 2006; 20: 1895–1897.
  CAS PubMed Google Scholar
• Florensa L, Bellosillo B, Besses C, Puigdecanet E, Espinet B, Pérez-Vila E et al. Jak2 V617F mutation analysis in different myeloid lineages (granulocytes, platelets, CFU-MK, BFU-E and CFU-GM) in essential thrombocythemia patients. Leukemia 2006; 20: 1903–1905.
  CAS PubMed Google Scholar
• Fiorini A, Farina G, Reddiconto G, Palladino M, Rossi E, Za T et al. Screening of Jak2 V617F mutation in multiple myeloma. Leukemia 2006; 20: 1912–1913.
  CAS PubMed Google Scholar
• Park MJ, Shimada A, Asada H, Koike K, Tsuchida M, Hayashi Y . Jak2 mutation in a boy with polycythemia vera, but not in other pediatric hematologic disorders. Leukemia 2006; 20: 1453–1454.
  CAS PubMed Google Scholar
• Chen CY, Lin LI, Tang JL, Tsay W, Chang HH, Yeh YC et al. Acquisition of Jak2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome. Leukemia 2006; 20: 1155–1158.
  PubMed Google Scholar
• Murati A, Adélaïde J, Gelsi-Boyer V, Etienne A, Rémy V, Fezoui H et al. t(5;12)(q23–31;p13) with ETV6-ACSL6 gene fusion in polycythemia vera. Leukemia 2006; 20: 1175–1178.
  CAS PubMed Google Scholar
• Yip SF, So CC, Chan AY, Liu HY, Wan TsK, Chan LC . The lack of association between Jak2 V617F mutation and myelodysplastic syndrome with or without myelofibrosis. Leukemia 2006; 20: 1165.
  CAS PubMed Google Scholar
• McClure R, Mai M, Lasho T . Validation of two clinically useful assays for evaluation of Jak2 V617F mutation in chronic myeloproliferative disorders. Leukemia 2006; 20: 168–171.
  CAS PubMed Google Scholar
• Melzner I, Weniger MA, Menz CK, Möller P . Absence of the Jak2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Leukemia 2006; 20: 157–158.
  CAS PubMed Google Scholar
• Bellosillo B, Besses C, Florensa L, Solé F, Serrano S . Jak2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among Ph-negative chronic myeloproliferative disorders. Leukemia 2006; 20: 736–737.
  CAS PubMed Google Scholar
• Desta F, Christiansen DH, Andersen MK, Pedersen-Bjergaard J . Activating mutations of Jak2V617F are uncommon in t-MDS and t-AML and are only observed in atypic cases. Leukemia 2006; 20: 547–548.
  CAS PubMed Google Scholar
• Vizmanos JL, Ormazábal C, Larráyoz MJ, Cross NC, Calasanz MJ . Jak2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients. Leukemia 2006; 20: 534–535.
  CAS PubMed Google Scholar
• Kratz CP, Böll S, Kontny U, Schrappe M, Niemeyer CM, Stanulla M . Mutational screen reveals a novel Jak2 mutation, L611S, in a child with acute lymphoblastic leukemia. Leukemia 2006; 20: 381–383.
  CAS PubMed Google Scholar
• James C, Delhommeau F, Marzac C, Teyssandier I, Couédic JP, Giraudier S et al. Detection of Jak2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 2006; 20: 350–353.
  CAS PubMed Google Scholar
• Ohyashiki K, Aota Y, Akahane D, Gotoh A, Miyazawa K, Kimura Y et al. The Jak2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia 2005; 19: 2359–2360.
  CAS PubMed Google Scholar
• Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V et al. Clinical implications of the Jak2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19: 1847–1849.
  CAS PubMed Google Scholar
• Chen CY, Lin LI, Tang JL, Tsay W, Chang HH, Yeh YC et al. Acquisition of Jak2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome. Leukemia 2006; 20: 1155–1158.
  PubMed Google Scholar
• Ray A, Cown-Jacob SW, Manley PW, Mestan J, Griffin JD . Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007; 109: 5011–5015.
  CAS PubMed Google Scholar
• Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117–125.
  CAS PubMed Google Scholar
• Nicolini FE, Corm S, Le Q-H, Sorel N, Hayette S, Bories D et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006; 20: 1061–1066.
  CAS PubMed Google Scholar
• Ma W, Kantarjian H, Jilani I, Gorre M, Bhalla K, Ottmann O et al. Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA. Leukemia 2006; 20: 1989–1991.
  CAS PubMed Google Scholar
• Miething C, Feihl S, Mugler C, Grundler R, von Bubnoff N, Lordick F et al. The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib. Leukemia 2006; 20: 650–657.
  CAS PubMed Google Scholar
• Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O’Brien S et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007; 110: 4005–4011.
  CAS PubMed Google Scholar
• Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ . MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007; 109: 500–502.
  CAS PubMed Google Scholar
• Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL et al. Sequential Abl kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007; 117: 2562–2569.
  CAS PubMed PubMed Central Google Scholar
• Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, Lupi R et al. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res 2007; 67: 7987–7990.
  CAS PubMed Google Scholar
• Peng C, Brian J, Hu Y, Goodrich A, Kong L, Grayzel D et al. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 2007; 110: 678–685.
  CAS PubMed PubMed Central Google Scholar
• Nguyen TK, Rahmani M, Harada H, Dent P, Grant S . MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood 2007; 109: 4006–4015.
  CAS PubMed PubMed Central Google Scholar
• Dong S, Kang S, Lonial S, Khoury HJ, Viallet J, Chen J . Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070. Leukemia 2008; 22: 572–577.
  CAS PubMed Google Scholar
• Zhang B, Groffen J, Heisterkamp N . Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells. Leukemia 2007; 21: 1189–1197.
  CAS PubMed Google Scholar
• Tagliafico E, Tenedini E, Manfredini R, Grande A, Ferrari F, Roncaglia E et al. Identification of a molecular signature predictive of sensitivity to differentiation induction in acute myeloid leukemia. Leukemia 2006; 20: 1751–1758.
  CAS PubMed Google Scholar
• Chung YJ, Kim TM, Kim DW, Namkoong H, Kim HK, Ha SA et al. Gene expression signatures associated with the resistance to imatinib. Leukemia 2006; 20: 1542–1550.
  CAS PubMed Google Scholar
• Cavo M . Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 2006; 20: 1341–1352.
  CAS PubMed Google Scholar
• Meier M, den Boer ML, Meijerink JP, Broekhuis MJ, Passier MM, van Wering ER et al. Differential expression of p73 isoforms in relation to drug resistance in childhood T-lineage acute lymphoblastic leukaemia. Leukemia 2006; 20: 1377–1384.
  CAS PubMed Google Scholar
• Karajannis MA, Vincent L, Direnzo R, Shmelkov SV, Zhang F, Feldman EJ et al. Activation of FGFR1beta signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells. Leukemia 2006; 20: 979–986.
  CAS PubMed Google Scholar
• Hamilton A, Elrick L, Myssina S, Copland M, Jørgensen H, Melo JV et al. BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. Leukemia 2006; 20: 1035–1039.
  CAS PubMed Google Scholar
• Blalock WL, Steelman LS, Shelton JG, Moye PW, Lee JT, Franklin RA et al. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia. Leukemia 2003; 17: 1058–1067.
  CAS PubMed Google Scholar
• Zhu K, Gerbino E, Beaupre DM, Mackley PA, Muro-Cacho C, Beam C et al. Farnesyltransferase inhibitor R115777 (zarnestra, tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood 2005; 105: 4759–4766.
  CAS PubMed PubMed Central Google Scholar
• Harousseau JL, Lancet JE, Reiffers J, Lowenberg B, Thomas X, Huguet F et al. A phase 2 study of the oral farnesyl transferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood 2007; 109: 5151–5156.
  CAS PubMed Google Scholar
• Sosman JA, Puzanov I, Atkins MB . Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res 2007; 13: 764s–7769s.
  CAS PubMed Google Scholar
• Dai Y, Landowski TH, Rosen ST, Dent P, Grant S . Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood 2002; 100: 3333–3343.
  CAS PubMed Google Scholar
• Lunghi P, Tabilio A, Lo-Coco F, Pelicci PG, Bonati A . Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells. Leukemia 2005; 19: 234–244.
  CAS PubMed Google Scholar
• Lunghi P, Costanzo A, Salvatore L, Noguera N, Mazzera L, Tabilio A et al. MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis. Blood 2006; 107: 4549–4553.
  CAS PubMed Google Scholar
• Rieber M, Rieber MS . Signalling responses linked to betulinic acid-induced apoptosis are antagonized by MEK inhibitor U0126 in adherent or 3D spheroid melanoma irrespective of p53 status. Int J Cancer 2006; 118: 1135–1143.
  CAS PubMed Google Scholar
• Tazzari PL, Tabellini G, Bortul R, Papa V, Evangelisti C, Grafone T et al. The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia 2007; 21: 886–896.
  CAS PubMed Google Scholar
• Hahn M, Li W, Yu C, Rahmani M, Dent P, Grant S . Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Mol Cancer Ther 2005; 4: 457–470.
  CAS PubMed Google Scholar
• Dai Y, Rahmani M, Pei XY, Khanna P, Han SI, Mitchell C et al. Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. Blood 2005; 105: 1706–1716.
  CAS PubMed Google Scholar
• Yu C, Mao X, Li WX . Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway. Biochem Biophys Res Commun 2005; 331: 391–397.
  CAS PubMed Google Scholar
• Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107: 4053–4062.
  CAS PubMed PubMed Central Google Scholar
• Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, deJong R et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 2005; 4: 977–986.
  CAS PubMed Google Scholar
• Pearce DJ, Taussig DJ, Bonnet D . Implications of the expression of myeloid markers on normal and leukemic stem cells. Cell Cycle 2006; 5: 271–273.
  CAS PubMed Google Scholar
• Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O’Conner J et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Orthod 2005; 23: 4110–4116.
  CAS Google Scholar
• Amadori S, Suciu S, Stasi R, Willemze R, Mandelli F, Selleslag D et al. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell’Adulto Leukemia Groups. Leukemia 2005; 19: 1768–1773.
  CAS PubMed Google Scholar
• Bertrand FE, Steelman LS, Chappell WH, Abrams SL, Shelton JG, White ER et al. Synergy between an IGF-IR antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia 2006; 20: 1254–1260.
  CAS PubMed Google Scholar
• Rizo A, Vellenga E, de Haan G, Schuringa JJ . Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche? Hum Mol Genet 2006; 15: 210–219.
  Google Scholar
• Li Z, Li L . Understanding hematopoietic stem-cell microenvironments. Trends Biochem Sci 2006; 31: 589–595.
  CAS PubMed Google Scholar
• Dalton WS, Hazlehurst L, Shain K, Landowski T, Alsina M . Targeting the bone marrow microenvironment in hematologic malignancies. Semin Hematol. 2004; 41: 1–5.
  CAS PubMed Google Scholar
• Katoh O, Takahashi T, Oguri T, Kuramoto K, Mihara K, Kobayashi M et al. Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor. Cancer Res 1998; 58: 5565–5569.
  CAS PubMed Google Scholar
• Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003; 9: 1158–1165.
  CAS PubMed Google Scholar
• Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, Priebe W et al. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res 2007; 67: 684–694.
  CAS PubMed Google Scholar
• Astier AL, Xu R, Svoboda M, Hinds E, Munoz O, de Beaumont R et al. Temporal gene expression profile of human precursor B leukemia cells induced by adhesion receptor: identification of pathways regulating B-cell survival. Blood 2003; 101: 1118–1127.
  CAS PubMed Google Scholar
• Mudry RE, Fortney JE, York T, Hall BM, Gibson LF . Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood 2000; 96: 1926–1932.
  CAS PubMed Google Scholar
• Ho AD, Wagner W . Bone marrow niche and leukemia. Ernst Schering Found Symp Proc 2006; 5: 125–139.
  Google Scholar
• Ravandi F, Estrov Z . Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clin Cancer Res 2006; 12: 340–344.
  CAS PubMed Google Scholar
• Goodell MA, Rosenzweig M, Kim H, Marks DR, DeMaria M, Paradis G et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997; 12: 1337–1345.
  Google Scholar
• Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001; 98: 1166–1173.
  CAS PubMed Google Scholar
• Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Margalit O, Avigdor A et al. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 2006; 20: 2147–2154.
  CAS PubMed Google Scholar
• Raaijmakers MHGP . ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutic targets in acute and chronic myeloid leukemia. Leukemia 2007; 21: 2094–2102.
  CAS PubMed Google Scholar
• Cheung AM, Wan TS, Leung JC, Chan LY, Huang H, Kwong YL et al. Aldehyde dehydrogenase activity in leukeic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 2007; 21: 1423–1430.
  CAS PubMed Google Scholar
• Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000; 14: 1777–1784.
  CAS PubMed Google Scholar
• Frankel AE, McCubrey JA, Miller MS, Delatte S, Ramage J, Kiser M et al. Diptheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia 2000; 14: 576–585.
  CAS PubMed Google Scholar
• Black JH, McCubrey JA, Willingham MC, Ramage J, Hogge DE, Frankel AE . Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice. Leukemia 2003; 17: 155–159.
  CAS PubMed Google Scholar
• Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926–935.
  CAS PubMed Google Scholar
• Jiang X, Saw KM, Eaves A, Eaves C . Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007; 99: 680–693.
  CAS PubMed Google Scholar
• Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M . Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 2006; 12: 1181–1184.
  CAS PubMed Google Scholar
• Mikesch JH, Steffen B, Berdel WE, Serve H, Muller-Tidow C . The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia. Leukemia 2007; 21: 1638–1647.
  CAS PubMed Google Scholar
• Levis M, Murphy KM, Pham R, Kim KT, Stine A, Li L et al. Internal tandem duplications of the Flt-3 gene are present in leukemia stem cells. Blood 2005; 106: 673–680.
  CAS PubMed PubMed Central Google Scholar
• Ysebaert L, Chicanne G, Demur C, De Toni F, Prade-Houdellier N, Ruidavets JB et al. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia 2006; 20: 1211–1216.
  CAS PubMed Google Scholar
• Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Hargalit O, Avigdor A et al. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 2006; 20: 2147–2154.
  CAS PubMed Google Scholar
• Hosen N, Shirakata T, Nishida S, Yanagihara M, Tsuboi A, Kawakami M et al. The Wilm's tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis. Leukemia 2007; 21: 1783–1791.
  CAS PubMed Google Scholar
• Wong P, Iwasaki M, Somervaille TC, So CW, Cleary ML . Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev 2007; 21: 2762–2774.
  CAS PubMed PubMed Central Google Scholar
• Steidl U, Rosenbauer F, Verhaak RG, Gu X, Ebralidze A, Out HH et al. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat Genet 2006; 38: 1269–1277.
  CAS PubMed Google Scholar
• Somervaille TC, Cleary ML . PU.1 and Junb: suppressing the formation of acute myeloid leukemia stem cells. Cancer Cell 2006; 10: 456–457.
  CAS PubMed Google Scholar
• McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochem Biophys Acta 2007; 1773: 1263–1284.
  CAS PubMed Google Scholar